Releaf, a leading UK medical marijuana provider, has entered into a major partnership with domestic cannabis producer Glass Pharms, marking a significant milestone for the UK medical cannabis industry. This deal, the largest of its kind in the UK, signifies the growing acceptance of medical cannabis as a legitimate healthcare solution and will ensure a reliable and consistent supply of high-quality medical cannabis for patients.
New Zealand’s cannabis landscape is evolving. While medical marijuana access has improved since 2020, concerns linger over potential profit-driven practices and high THC flower dominance. Meanwhile, the hemp industry is advocating for deregulation, highlighting its economic and environmental potential.
A recent decision by the Arizona Court of Appeals has ignited debate as it allows medical marijuana dispensaries to operate near preschools. The ruling stems from a legal challenge against the state’s 500-foot buffer zone requirement for schools, prompting concerns about the proximity of marijuana businesses to young children.
The cannabis landscape in Europe continues to evolve. This article explores recent developments in the UK, the Netherlands, and Poland, highlighting ongoing medical marijuana trials, declining cultivation in the Netherlands, and rising demand for medical cannabis in Poland.
A retired Navy veteran from Georgia, Charles Wimberly, faces an uncertain legal situation in Dubai after being arrested for possessing medically prescribed CBD pills. Despite presenting his prescription, authorities accused him of drug trafficking, highlighting the strict laws against CBD in the UAE. Wimberly’s family and legal advocates are seeking his release, emphasizing the potential health risks associated with his detainment and the unclear legal grounds for his arrest.
As Connecticut transitions to recreational cannabis, concerns are emerging about the impact on medical marijuana patients. The state’s cannabis ombudsman, Erin Gorman Kirk, highlights the challenges faced by patients, including limited product availability and high prices. Venture capitalist Matt Hawkins explains how the shift to recreational use often impacts medical programs across the US, and he discusses different licensing models and their implications for investment.
The shift from medical to recreational marijuana use in Connecticut has sparked concern about the welfare of medical patients, as many are finding it difficult to access the high-quality products they need. This article delves into the challenges facing the state’s cannabis industry, including a lack of consistent medication, rising prices, and the potential for predatory practices in the licensing process.
While recreational cannabis markets boom, industry experts like Brandon Harshbarger, president of Cheech and Chong Global Holdings, express concern over the diminishing focus on medical marijuana. Harshbarger emphasizes the importance of medical cannabis in the initial push for legalization and fears that the industry’s focus on recreational use may overshadow its medicinal benefits.
A new study published in JAMA Network Open reveals a significant difference in opinion regarding cannabis access between chronic pain patients and their physicians. While patients overwhelmingly support policies that expand access to medical marijuana, physicians tend to favor stricter regulations and access control.
Luna Stower, Chief Impact Officer at Ispire, emphasizes the critical need to prioritize medical marijuana in cannabis policy discussions. Despite the focus on adult-use legalization, Stower argues that medical cannabis remains fundamental to the movement, providing essential relief to patients suffering from chronic conditions. She also highlights the crucial role of medical marijuana in shaping global cannabis regulations, particularly in countries hesitant about full legalization.
